Cnbx Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OID
3i, LP and associated entities report a 9.9% beneficial ownership stake in CNBX Pharmaceuticals following recent share issuances.
OID
SCHEDULE: 3i LP Updates CNBX Pharma Stake to 9.99%
3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has updated its beneficial ownership in CNBX Pharmaceuticals Inc. to 9.99% through a convertible note.
OID
3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has updated its beneficial ownership in CNBX Pharmaceuticals Inc. to 9.99%, comprising direct shares and convertible note holdings.
OID
SCHEDULE: 3i LP Boosts CNBX Pharma Stake to 9.9%
3i, LP and its affiliates have updated their beneficial ownership in CNBX Pharmaceuticals Inc. to 9.9% of outstanding common stock, totaling 13,573,116 shares.
OID
SCHEDULE 13G/A: 3i LP and Affiliates Maintain 9.9% Stake in CNBX Pharmaceuticals, Update Beneficial Ownership Filing
3i, LP, 3i Management LLC, and Maier Joshua Tarlow have filed an Amendment No. 4 to their Schedule 13G, reporting a combined beneficial ownership of 9.9% of CNBX Pharmaceuticals Inc.'s common stock as of March 31, 2025.
OID
SCHEDULE 13G/A: 3i LP Updates Significant Stake in CNBX Pharmaceuticals, Maintaining 9.9% Beneficial Ownership
3i, LP, along with its affiliates, has filed an Amendment No. 3 to its Schedule 13G, reaffirming its beneficial ownership of 9.9% of CNBX Pharmaceuticals Inc.'s common stock as of December 31, 2024.